Clostridium difficile

Disease-a-Month

Volumn 55, Issue 7, 2009, Pages 439-470

  McFee, Robin B ^a   Abdelsayed, George G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BACTERIAL VACCINE; CEFAZOLIN; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE VACCINE; COLESTYRAMINE; DEPSIPEPTIDE; FRUCTOSE OLIGOSACCHARIDE; FUSIDIC ACID; GATIFLOXACIN; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN; METRONIDAZOLE; MOXIFLOXACIN; NISIN; NITAZOXANIDE; PENICILLIN DERIVATIVE; PLACEBO; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAXIMIN; RIMOPLANIN; TEICOPLANIN; TOLEVAMER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANAMNESIS; ANTIBIOTIC RESISTANCE; ANTIBODY PRODUCTION; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM EXAMINATION; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; DIARRHEA; DRUG ABSORPTION; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENVIRONMENTAL SANITATION; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVIDENCE BASED PRACTICE; FECES CULTURE; FECES MICROFLORA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HAND WASHING; HEALTH EDUCATION; HEARTBURN; HOSPITAL INFECTION; HUMAN; HYPERCHOLESTEROLEMIA; INFECTION CONTROL; INFECTION RATE; LABORATORY TEST; LACTOBACILLUS; LATEX AGGLUTINATION TEST; MORTALITY; NONHUMAN; PERSONAL HYGIENE; PSEUDOMEMBRANOUS COLITIS; RECURRENT INFECTION; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SACCHAROMYCES; STRAIN DIFFERENCE; STRESS ULCER; TOXIN ANALYSIS; TRAVELLER DIARRHEA; VACCINE PRODUCTION;

ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DIARRHEA; HUMANS; INFECTION CONTROL; RECURRENCE; RISK FACTORS; UNITED STATES;

EID: 67149135203     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.disamonth.2009.04.010     Document Type: Review

References (82)

1. Centers for Disease Control and Prevention. Clostridium difficile infections. http://www.cdc.gov/ncidod/dhqp/id_cdiff_data.html
2. Walbrown M.A., Aspinall S.L., Bayliss N.K., et al. Evaluation of Clostridium difficile-associated diarrhea with a drug formulary change in preferred flouroquinolones. J Manag Care Pharm 14 1 (2008) 34-40
3. O'Connor J. C diff-Rise in UK deaths: 72% increase between 2005 and 2006 (2008). http://patient-health-education.suite101.com/article.cfm/c_difficile_rise_in_uk_deaths Feb 28, Last accessed 6/24/08
4. Kyne L. Health care associated costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 34 (2002) 346-353
5. Scheurer D.B., Hicks L.S., Cook E.F., et al. Short report-Accuracy of ICD-9 coding for Clostridium difficile infections: A retrospective cohort. Epidemiol Infect 135 (2007) 1010-1013
6. Zerey M., Paton B.L., Lincourt A.E., et al. The burden of Clostridium difficile in surgical patients in the United States. Surg Infect (Larchmt) 8 6 (2007) 557-566
7. Deaths involving MRSA and Clostridium difficile continue to rise. Health statistics. Quarterly Spring 2007; Febr 22, 2007. Issued by the Office of National Statistics, London SW1V 2QQ. http://www.statistics.gov.uk/releases.
8. Fordtran J.S. Colitis due to Clostridium difficile toxins: Underdiagnosed, highly virulent, and nosocomial. Proc Bayl Univ Med Cent 19 (2006) 3-12
9. Dramatic rise in C diff deaths. BBC News February 28, 2008. http://news.bbc.co.uk/1/hi/health/7268578.stm Last accessed 8/12/08
10. Sunenshine R.H., and McDonald L.C. Clostridium difficile-associated disease: New challenges from an established pathogen. Cleve Clin J Med 73 2 (2006) 187-197
11. Friedenberg F.K. Clostridium difficile associated disease: Changing epidemiology and treatment options. Medscape Gastroenterology. http://www.medscape.com/viewarticle/563386_print Last accessed 6/25/08
12. Ashu N.J., Tompkins D., and Wilcox M.H. Comparative analysis of prevalence, risk factors and molecular epidemiology of antibiotic associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus. J Clin Microbiol 44 (2006) 2785-2791
13. Kuijper E.J., and Coignard T.P. Emergence of Clostridium difficile associated disease in North America and Europe. Clin Microbiol Infect 12 (2006) 2-18
14. McDonald L.C., Kilgore G.E., Thomson A., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353 (2005) 2433-2441
15. Jarvis W.R. Infection control and changing health care delivery systems. Emerg Infect Dis 7 2 (2001) 170-173
16. Klevens R.M., Edwards J.R., Richards C.L., et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Pub Health Rep 122 (2007) 160-166
17. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Cont 32 (2004) 470-485
18. CDC NNIS system. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992-June 2003. Issued August 2003. Am J Infect Cont 31 (2003) 481-498
19. Edwards J.R., Peterson K.D., Andrus M.L., et al. National Healthcare Safety Network (NHSN) Report. Data summary for 2006, issued 2007. Am J Infect Cont 35 (2007) 290-301
20. Centers for Disease Control and Prevention (CDC). Outline for health care-associated infection surveillance. http://www.cdc.gov/ncidod/dhqp/nhsn+documents.html
21. Johal S.S., Hammond J., Solomon K., et al. Clostridium difficile associated diarrhea in hospitalized patients: Onset in the community and hospital and role of flexible sigmoidoscopy. Gut 53 ;5 (2004) 673-677
22. Clostridium difficile. In: Aberg J.A., Goldman M.P., Gray L.D., et al. (Eds). Infectious Diseases Handbook Including Antimicrobial Therapy & Diagnostic Tests/Procedures. 6th ed. (2005), Lexi-Comp, Hudson, OH 83-86
23. Halsey J. Current and future treatment modalities for Clostridium difficile associated disease. Am J Health Syst Pharm 65 (2008) 705-715
24. Drudy D., Harnedy N., Fanning S., et al. Emergence and control of fluoroquinolone resistant, toxin A negative, toxin B positive Clostridium difficile. Infect Cont Hosp Epidemiol 28 8 (2007) 932-940
25. Kim J., Smathers S.A., Prasad P., et al. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics 122 (2008) 1266-1270
26. Moss L. Hospital Clostridium difficile deaths: The patients let down by those they trusted. http://news.scotsman.com/latestnews/-Hospital-c-difficile-deaths.4370831.jp August 12, 2008. http://news.scotsman.com/latestnews/-Hospital-c-difficile-deaths.4370831.jp
27. O'Connor J. C diff-Rise in UK deaths: 72% increase between 2005 and 2006 (2008). http://patient-health-education.suite101.com/article.cfm/c_difficile_rise_in_uk_deaths Feb 28, Last accessed 6/24/08
28. Christensen M., and Jepsen O.B. Reduced rates of hospital acquired UTI in medical patients. Prevalence surveys indicated effect of active infection control programmes. J Hosp Infect 47 (2001) 36-40
29. Provincial Infectious Diseases Advisory Committee (PIDAC). Best practices document for the management of Clostridium difficile in all health care settings. Ministry of Health and Long Term Care. Published December 2004, Revised November 2007.
30. Nelson R.L. Antibiotic treatment for Clostridium difficile associated diarrhea in adults. Cochrane Datatbase Syst Rev (2008) 4
31. Joint Commission Accreditation Healthcare Organizations (JCAHO). http://www.jointcommission.org/
32. Boyce J.M., and Pittet D. Guidelines for Hand Hygiene in Health Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. A report of the CDC. MMWR Morb Mortal Wkly Rep 51 (2002) RR-16
33. Institute for healthcare improvement. Saving 100,000 lives campaign. http://www.ihi.org
34. Association for Professionals in Infection Control and epidemiology (APIC). Government advocacy. http://www.apic.org/content/navigationmenu/governmentadvocacy/mandatoryreporting/abouttheissue/about_the_issue.htm
35. Burke J.P. Infection control-A problem for patient safety. N Engl J Med 348 (2004) 651-656
36. Pepin J., Saheb N., Coulombe M.A., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile associated diarrhea. Clin Infect Dis 41 (2005) 1254-1260
37. Cunningham R., and Dial S. Is over use of proton pump inhibitors fueling the current epidemic of Clostridium difficile associated diarrhea?. J Hosp Infect 70 ;1 (2008) 1-6
38. Aseeri M., Schroeder T., Kramer J., et al. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile associated diarrhea in hospitalized patients. Am J Gastroenterol 103 ;9 (2008) 2308-2313
39. Akhtar A.J., and Shaheen M. Increasing incidence of Clostridium difficile associated diarrhea in African American and Hispanic patients: Association with the use of proton pump inhibitor therapy. J Natl Med Assoc 99 5 (2007) 500-504
40. Sprague L. Health care-associated infections: is there an end in sight?. Issue Brief Natl Health Policy Forum 830 (2009) 1-14
41. Pepin J., Valiquette L., Alary M.E., et al. Clostridium difficile associated diarrhea in a region of Quebec from 1991-2003; a changing pattern of disease severity. CMAJ 171 (2004) 466-472
42. Fenner L., Widmer A.F., Goy G., et al. Rapid and reliable diagnostic algorithm for detection of Clostridium difficile. J Clin Microbiol 46 (2008) 328-330
43. Boyce J.M. Hand hygiene compliance monitoring: Current perspectives from the USA. J Hosp Infect 70 (2008) 2-7 Oct
44. Hooper D.C. Emerging mechanisms of fluoroquinolone. Resistance 7 2 (2001) 337-341
45. Al Tureihi F.J., Hassoun A., Wolf-Klein G., et al. Albumin, length of stay and proton pump inhibitors: Key factors in Clostridium difficile associated disease in nursing home patients. J Am Med Dir Assoc 6 (2005) 105-108
46. Dial S., Delaney J.A., Barkun A.N., et al. Use of gastric acid suppressive agents and the risk of community acquired Clostridium difficile associated disease. J Am Med Assoc 294 (2005) 2989-2995
47. Cunningham R., Dale B., Undy B., et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhea. J Hosp Infect 54 (2003) 243-245
48. Dallal R.M., Harbrecht B.G., Boujoukas A.J., et al. Fulminant Clostridium difficile an underappreciated and increasing cause of death and complications. Ann Surg 235 (2002) 363-372
49. Creedon S.A. Healthcare workers' hand decontamination practices: Compliance with recommended guidelines. J Adv Nurs 51 ;3 (2005) 208-216
50. Warny M., Pepin J., Fang A., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North American and Europe. Lancet 366 (2005) 1079-1084
51. McDonald L.C., Killgore G.E., Thompson A., et al. An epidemic toxin gene variant strain of Clostridium difficile. N Engl J Med 353 (2005) 2433-2441
52. Rupnik M., Brazier J.S., Duertden B.L., et al. Comparison of toxino-typing and PCR ribotyping of Clostridium difficile strains and description of novel toxinotypes. Microbiology 147 (2001) 439-447
53. Rupnik M., Kato N., Grabnar M., et al. New types of toxin A negative, toxin B positive strains among Clostridium difficile isolates from Asia. J Clin Microbiol 41 (2003) 1118-1125
54. Geric C., Rupnik M., Gerding D.N., et al. Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin gene among clinical isolates in an American Hospital. J Med Microbiol 53 (2004) 887-894
55. McCannell D.R., Louie T.J., Gregson D.B., et al. Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada. J Clin Microbiol 44 (2006) 2147-2152
56. Thomas C., Stevenson M., and Riley T. Antibiotics and hospital acquired Clostridium difficile associated diarrhea: A systemic review. J Antimicrob Chemother 51 6 (2003) 1339-1350
57. Gerding D.N., Jonson S., Peterson L.R., et al. Clostridium difficile associated diarrhea and colitis. Infect Cont Hosp Epidemiol 16 (1995) 459-477
58. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile associated diarrhea and colitis. Am J Gastroenterol 92 (1997) 739-750
59. American Society of Health System Pharmacists A.S.H.P. Therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile associated disease. Am J Health Syst Pharm 55 (1998) 1407-1411
60. Guerrant R.L., Van Gilder T., Steiner T.S., et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Disord 32 (2001) 331-351
61. Flagyl (Metronidazole) Package Insert (2004), Pharmacia, Chicago, IL
62. Vancocin (Vancomycin Hydrochloride) Package Insert (2005), ViroPharma, Exton, PA
63. Teasley D.G., Gerding D.N., Olson M.M., et al. Prospective randomized trial of metronidazole versus vancomycin for Clostridium difficile associated diarrhea and colitis. Lancet 2 (1983) 1043-1046
64. Kelly C.P., Pothoulakis C., and LaMont I.T. Clostridium difficile colitis. N Engl J Med 330 (1994) 257
65. McFarland L.V., Elmer G.W., and Surawicz C.M. Breaking the cycle: Treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 97 (2002) 1770-1775
66. In: Kucers A., and Bennett N.M. (Eds). The Use of Antibiotics. 4th ed. (1987), Lippincott, Philadelphia, PA
67. Wullt M., and Odenholt I. A double blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile associated diarrhea. J Antimicrob Chemother 54 (2004) 211-216
68. De Lalla F., Nicolin R., Rinaldi E., et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile associated diarrhea. Antimicrob Agents Chemother 36 (1992) 2192-2196
69. Wenisch C., Parschalk B., Hasenhundl M., et al. Comparison of vancomycin, teicoplanin, metronidazole and fusidic acid for the treatment of Clostridium difficile associated diarrhea. Clin Infect Dis 22 (1996) 813-818 [Erratum 1996:23:423]
70. Johnson S., Schriever C., Galang M., et al. Interruption of recurrent Clostridium difficile associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 44 (2007) 846-848
71. Taylor N.S., and Bartlett J.G. Binding of Clostridium difficile cytotoxin and vancomycin by anion exchange resins. J Infect Dis 141 (1980) 92-97
72. Kruetzer E.W., and Milligan F.D. Treatment of antibiotic associated pseudomembranous colitis with cholestyramine resin. Johns Hopkins Med J 143 (1978) 67-72
73. Scott V.N., and Taylor S.L. Effect of nisin on the outgrowth of Clostridium botulinum spores. J Food Sci 46 (1981) 117-120
74. Kyne L., Warny M., Qamar A., et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 342 (2000) 390-397
75. Naaber P., smidt I., Stsepetova J., et al. Inhibition of Clostridium difficile strains by intestinal lactobacillus species. J Med Microbiol 53 (2004) 551-554
76. Can M., Besirbellioglu B.A., Avci I.Y., et al. Prophylactic Saccharomyces boulardii in the prevention of antibiotic associated diarrhea: A prospective study. Med Sci Monit 12 (2006) 119-122
77. Lewis S., Burmeister S., and Brazier J. Effect of the probiotic oligofructose on relapse of Clostridium difficile associated diarrhea: A randomized controlled study. Clin Gastroenterol Hepatol 3 (2005) 442-448
78. Aas J., Gessert C.E., and Bakken J.S. Recurrent Clostridium difficile colitis: Case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 36 (2003) 580-585
79. Zigmund J. No more room; overcrowding blamed for ambulance diversions http://Modernhealthcare.com Available at: http://www.modernhealthcare.com/printwindow.cms?articleId=38689&pageType=article.
80. Langmuir A.D. Changing concepts of airborne infection of acute contagious diseases: a reconsideration of classic epidemiologic theories. Ann NY Acad Sci 353 (1980) 35-44
81. Kotloff K.L., Wasserman S.S., Losonsky G.A., et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 69 (2001) 988-995
82. Pechine S., Janoir C., and Collignon A. Variability of Clostridium difficile surface proteins and specific serum antibody response in patients with Clostridium difficile associated disease. J Clin Microbiol 43 (2005) 5018-5025